CDAP structure
|
Common Name | CDAP | ||
|---|---|---|---|---|
| CAS Number | 59016-56-7 | Molecular Weight | 234.99 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C8H10BF4N3 | Melting Point | 196-200ºC | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of CDAPCDAP is a biochemical reagent that can be used as a biological material or organic compound for life science related research. |
| Name | 1-Cyano-4-dimethylaminopyridinium tetrafluoroborate |
|---|---|
| Synonym | More Synonyms |
| Description | CDAP is a biochemical reagent that can be used as a biological material or organic compound for life science related research. |
|---|---|
| Related Catalog |
| Melting Point | 196-200ºC |
|---|---|
| Molecular Formula | C8H10BF4N3 |
| Molecular Weight | 234.99 |
| Exact Mass | 235.090393 |
| PSA | 30.91000 |
| LogP | 1.66928 |
| InChIKey | MBLVMDCQDCVKNE-UHFFFAOYSA-N |
| SMILES | CN(C)c1cc[n+](C#N)cc1.F[B-](F)(F)F |
| Storage condition | 2~8°C |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi,Xn |
| Risk Phrases | R36/37/38 |
| Safety Phrases | S26-S36 |
| RIDADR | UN 1759 |
| WGK Germany | 3.0 |
| Packaging Group | III |
| Hazard Class | 8.0 |
| HS Code | 2933399090 |
| HS Code | 2933399090 |
|---|---|
| Summary | 2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|
Preparation and testing of a Haemophilus influenzae Type b/Hepatitis B surface antigen conjugate vaccine.
Vaccine 33(13) , 1614-9, (2015) The majority of conjugate vaccines focus on inducing an antibody response to the polysaccharide antigen and the carrier protein is present primarily to induce a T-cell dependent response. In this stud... |
|
|
Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice.
Infect. Immun. 71(9) , 5115-20, (2003) Epidemic and endemic meningitis caused by group A Neisseria meningitidis remains a problem in sub-Saharan Africa. Although group A meningococcal capsular polysaccharide (GAMP) vaccine confers immunity... |
|
|
Surfactant-assisted lipopolysaccharide conjugation employing a cyanopyridinium agent and its application to a competitive assay.
Anal. Chem. 81 , 3824-9, (2009) The activation of a lipopolysaccharide (LPS) with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) in the presence of a surfactant allows an efficient conjugation with dansyl hydrazine or ho... |
| N-(1-cyanopyridin-4(1H)-ylidene)-N-methylmethanaminium tetrafluoroborate |
| 1-Cyano-4-(dimethylamino)pyridinium tetrafluoroborate |
| 4-(dimethylamino)pyridin-1-ium-1-carbonitrile,tetrafluoroborate |
| 1-Cyano-N,N-dimethyl-4(1H)-pyridiniminium tetrafluoroborate |
| 1-Cyano-4-dimethylaminopyridinium tetrafluoroborate |